Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023

NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...

2023-04-11 20:00 1996

Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"

SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...

2023-04-10 20:18 2827

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...

2023-04-07 16:34 5177

Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")

SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...

2023-04-07 10:00 2960

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ -- BIORCHESTRA , a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) leveraging the Biorchestra Drug Delivery System (BDDSTM), w...

2023-04-05 20:00 3385

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration toinitiate a Phase 2 clinical trial of BS...

2023-04-04 20:50 2637

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 20:00 3468

GC Cell and New Management Embarking on a New Chapter

* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...

2023-04-03 16:47 3175

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncolo...

2023-04-03 15:10 4445

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-m...

2023-04-03 13:44 2587

CBC Group Appoints Healthcare Veteran Abbas Hussain as Operating Partner

SINGAPORE, March 31, 2023 /PRNewswire/ -- Singapore-headquartered asset management firm, CBC Group ("CBC"), is pleased to announce the appointment of healthcare industry veteran, Abbas Hussain, as Operating Partner. In this role, Abbas will closely partner with CBC's business teams to identify, ...

2023-04-01 10:00 4988

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus * Thirteen key clinical milestones...

2023-03-31 18:30 5143

Boao Forum for Asia Enters the Healthcare Sector

Boao Lecheng International Medical Tourism Pilot Zone at Hainan Free Trade Port Helps China's Medical Sector Expand into Global Markets QIONGHAI, China, March 30, 2023 /PRNewswire/ -- Boao, the seaside resort and convention destination on the South China Sea coast, has again caught the attention...

2023-03-31 10:00 2231

Genscript Biotech Reports 2022 Annual Results*

Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...

2023-03-31 08:40 3935

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended31 Decembe...

2023-03-31 00:33 4196

Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "...

2023-03-30 21:00 2818

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...

2023-03-30 18:54 2623

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...

2023-03-30 08:00 2505

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases

-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...

2023-03-29 22:00 2654

HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth

* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...

2023-03-29 19:00 2203

1 ... 117 118 119120121 122 123 ... 164